Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Salarius Pharmaceuticals, Inc. (SLRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2380-0.0051 (-2.10%)
At close: 04:00PM EDT
0.2351 -0.00 (-1.22%)
After hours: 05:16PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2431
Open0.2443
Bid0.2325 x 800
Ask0.2400 x 4000
Day's Range0.2300 - 0.2443
52 Week Range0.1600 - 1.2000
Volume298,591
Avg. Volume891,016
Market Cap10.759M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

    Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call and webcast today at 11:00 a.m. ETHOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and

  • GlobeNewswire

    Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

    Clinical Trial Now Expands to Fifteen U.S. Trial SitesHOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the addition of four prestigious institutions to the open-label Phase 1/2 trial with seclidemstat in Ewing’s sarcoma and FET-rearranged sarcomas. The Seattle Cancer Care Alliance (SCCA) – which is comprised of the Fred Hutc

  • GlobeNewswire

    Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

    HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, today announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition’s Nu.Q® technology to support further development of Salarius’ clinical stage d

Advertisement
Advertisement